Literature DB >> 14696760

Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.

Santo Morabito1, Isabella Guzzo, Angela Solazzo, Lina Muzi, Remo Luciani, Alessandro Pierucci.   

Abstract

BACKGROUND: The ongoing necessity for systemic heparinization is a well-known disadvantage of continuous renal replacement therapies (CRRT), and alternative methods of anticoagulation may be required. Our aim was to evaluate, in patients with a high risk of bleeding, the possibility of an acceptable filter life with non-anticoagulation CRRT and, in case of early filter failure, the efficacy and safety of bedside monitored regional anticoagulation with heparin and protamine.
METHODS: Fifty-nine patients underwent CRRT for acute renal failure (ARF) following cardiac surgery. Patients who fulfilled one of the following criteria were selected for non-anticoagulation CRRT: spontaneous bleeding, aPTT > 45 sec, thrombocytopenia and recent surgery (< 48 hr). Filter life < 24 hr without anticoagulation was the cut-off point for starting the regional anticoagulation CRRT. Heparin was infused pre-filter and protamine post-filter at an initial ratio of 1 mg protamine:100 IU heparin. The ratio was adjusted to achieve a patient aPTT < 45 sec and a circuit > 55 sec.
RESULTS: Twenty-two (37.3%) patients had been selected for non-anticoagulation. Of them, 12 patients continued to receive non-anticoagulation (filter life: 38.3 +/- 30.5 hr) while 10 switched to regional anticoagulation (filter life: 38.6 +/- 25 hr). During regional anticoagulation no statistical difference was found between baseline aPTT (36.7 +/- 6.4 sec) and patient aPTT (41.5 +/- 12.6 sec) while circuit aPTT (77.7 +/- 43.3 sec) was significantly higher than patient aPTT (p < 0.0001). The probabilities of the circuits remaining free from clotting after 24, 48 and 72 hr were: a) non-anticoagulation: 55.5%, 30.1% and 16.6%, b) regional anticoagulation: 76.2%, 39.6% and 19.8%. There was no rebound anticoagulation observed after regional anticoagulation CRRT ended.
CONCLUSIONS: Non-anticoagulation CRRT allowed an adequate filter life in most patients with a high risk of bleeding for prolonged aPTT and/or thrombocytopenia. Despite concerns regarding the need for careful monitoring, regional anticoagulation with heparin and protamine can be considered as a safe and valid alternative when non-anticoagulation is unsuitable because of early filter failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696760

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  14 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group "Renal Replacement Therapies in Critically Ill Patients" of the Italian Society of Nephrology.

Authors:  Enrico Fiaccadori; Valentina Pistolesi; Filippo Mariano; Elena Mancini; Giorgio Canepari; Paola Inguaggiato; Marco Pozzato; Santo Morabito
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

3.  Continuous renal replacement treatment and the 'bleeding patient'.

Authors:  Hugh Davies; Gavin Leslie; David Morgan
Journal:  BMJ Case Rep       Date:  2011-01-11

Review 4.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

5.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

6.  Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Laura Zeppilli; Francesca Polistena; Emanuela Strampelli; Alessandro Pierucci
Journal:  Crit Care       Date:  2012-06-27       Impact factor: 9.097

7.  Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.

Authors:  Josée Bouchard; François Madore
Journal:  NDT Plus       Date:  2008-12-09

8.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

9.  Regional citrate anticoagulation in CVVH: a new protocol combining citrate solution with a phosphate-containing replacement fluid.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Laura Zeppilli; Francesca Polistena; Enrico Fiaccadori; Alessandro Pierucci
Journal:  Hemodial Int       Date:  2012-08-07       Impact factor: 1.812

10.  Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.

Authors:  Andreas Link; Matthias Girndt; Simina Selejan; Ranja Rbah; Michael Böhm
Journal:  Crit Care       Date:  2008-08-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.